➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 4,664,912

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,664,912
Title: Process for the large scale production of rabies vaccine
Abstract:In the large-scale production of rabies vaccine a cell stock comprising a VERO cell strain and a liquid nutritive medium containing serum and microcarriers suspended therein is successively passed into biogenerators of increasing volume. The last of the passages is carried out in a biogenerator having a volume of at least 150 liters. The liquid nutritive medium is drawn off at the end of the final passage and replaced with a serum-free liquid nutritive medium. The cell stock is inoculated in the last passage biogenerator with virus which is allowed to develop. The virus is then cultured, withdrawn and filtered. The filtered liquid suspension is then ultrafiltered, with inactivated beta-propiolactone and purified by zonal centrifugation or chromatography.
Inventor(s): Wiktor; Tadeusz J. (Wynnewood, PA), Fanget; Bernard J. (Fleurieux sur l\'Arbresle 69 210, FR), Fournier; Pierre (69 005 Lyon, FR), Montagnon; Bernard J. (69 210 L\'Arbresle, FR)
Application Number:06/656,762
Patent Claims:see list of patent claims

Details for Patent 4,664,912

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline Biologicals Sa RABAVERT rabies vaccine KIT 103334 1 2016-12-19   Start Trial 2040-01-28 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.